论文部分内容阅读
为了解卵巢癌内在性的耐药机制 ,用免疫组织化学方法对 30例正常卵巢组织及术前未经治疗的 74例卵巢癌进行了 P-糖蛋白 (P- gp)与谷胱甘肽 S-转移酶 π(GST- π)的检测 ,结果表明 :正常卵巢组织中 ,P- gp与 GST- π的阳性率分别为 1 8.9%及 74.3% ,与对照组相比 ,均有显著性差异 (P <0 .0 5 ,P <0 .0 1 )。卵巢癌中 ,单独表达一种耐药标志的有 38例 (5 1 .4% ) ,同时表达两种耐药标志的有 1 4例 (1 8.9% ) ,而且 P- gp与 GST- π的表达具有显著的相关性 (P <0 .0 1 )。结果提示 :未经治疗的卵巢癌中存在着由 P - gp与 GST- π介导的内在性的耐药机制 ,这两种耐药标志的表达 ,可能在卵巢癌的化疗耐药中起着一定的作用。
To understand the intrinsic mechanism of drug resistance in ovarian cancer, 30 cases of normal ovarian tissue and 74 cases of preoperative ovarian cancer were treated with P-glycoprotein (P-gp) and glutathione S - transferase π (GST-π) test results showed that: normal ovary tissue, the positive rates of P-gp and GST-π were 1 8.9% and 74.3%, respectively, compared with the control group, there was a significant difference (P <0. 05, P <0. 01). In ovarian cancer, 38 cases (51.4%) expressed a single drug resistance marker alone and 14 cases (18.9%) expressed two drug resistance markers simultaneously, and the ratio of P-gp to GST-π Expression was significantly correlated (P <0.01). The results suggest that there is an intrinsic mechanism of resistance mediated by P - gp and GST - π in untreated ovarian cancer. The expression of these two drug resistance markers may play a role in chemoresistance in ovarian cancer A certain role.